PLRX - Pliant Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
PLRX price evolution
PLRX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $81.87 | $115.78 | $64.72 | |
| Short term investments | $356.22 | $368.09 | $431.01 | |
| Net receivables | $2.22 | $2.8 | $2.31 | $3 |
| Inventory | ||||
| Total current assets | $410.03 | $447.55 | $489.9 | $505.5 |
| Long term investments | ||||
| Property, plant & equipment | $33.73 | $34.26 | $29.83 | $4.78 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $36.18 | $31.71 | $6.65 | |
| Total investments | $356.22 | $368.09 | $431.01 | |
| Total assets | $445.67 | $483.73 | $521.61 | $512.15 |
| Current liabilities | ||||
| Accounts payable | $6.89 | $3.25 | $7.33 | $4.53 |
| Deferred revenue | ||||
| Short long term debt | $0.1 | $0.77 | $1.32 | |
| Total current liabilities | $39.95 | $30.92 | $30.39 | $28.52 |
| Long term debt | $30.14 | $60.13 | $53.88 | $10.05 |
| Total noncurrent liabilities | $60.13 | $53.88 | $10.05 | |
| Total debt | $60.23 | $54.66 | $11.37 | |
| Total liabilities | $99.84 | $91.05 | $84.27 | $38.58 |
| Shareholders' equity | ||||
| Retained earnings | -$660.32 | -$602.56 | -$546.7 | -$499.75 |
| Other shareholder equity | $0.85 | -$0.62 | -$0.49 | $0.34 |
| Total shareholder equity | $392.68 | $437.33 | $473.58 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $64.72 | $33.69 | $51.66 | $50.88 |
| Short term investments | $431.01 | $297.5 | $148.93 | $226.01 |
| Net receivables | $3 | $2.07 | $2 | $9.28 |
| Inventory | ||||
| Total current assets | $505.5 | $340.31 | $209.44 | $290.75 |
| Long term investments | ||||
| Property, plant & equipment | $4.78 | $9.91 | $10.94 | $4.32 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $6.65 | $10.3 | $11.77 | $4.77 |
| Total investments | $431.01 | $297.5 | $148.93 | $226.01 |
| Total assets | $512.15 | $350.61 | $221.22 | $295.53 |
| Current liabilities | ||||
| Accounts payable | $4.53 | $1.58 | $2.97 | $2.02 |
| Deferred revenue | ||||
| Short long term debt | $1.32 | $2.46 | $1.87 | |
| Total current liabilities | $28.52 | $23.91 | $16.83 | $11.6 |
| Long term debt | $10.05 | $9.93 | $5.33 | |
| Total noncurrent liabilities | $10.05 | $13.36 | $5.33 | $0.87 |
| Total debt | $11.37 | $15.81 | $7.19 | |
| Total liabilities | $38.58 | $37.27 | $22.16 | $12.46 |
| Shareholders' equity | ||||
| Retained earnings | -$499.75 | -$338.41 | -$215.09 | -$117.83 |
| Other shareholder equity | $0.34 | -$1.96 | -$0.2 | -$0.03 |
| Total shareholder equity | $473.58 | $313.34 | $199.06 | $283.06 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $45.62 | $37.15 | $33.18 | |
| Selling, general & administrative | $15.02 | $15.25 | $13.85 | |
| Total operating expenses | $62.01 | $60.64 | $52.39 | $47.04 |
| Operating income | -$60.64 | -$52.39 | -$47.04 | |
| Income from continuing operations | ||||
| EBIT | -$54.99 | -$46.51 | -$40.79 | |
| Income tax expense | ||||
| Interest expense | $4.25 | $0.87 | $0.45 | $0.32 |
| Net income | ||||
| Net income | -$57.76 | -$55.85 | -$46.95 | -$41.11 |
| Income (for common shares) | -$55.85 | -$46.95 | -$41.11 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.58 | $9.69 | $7.57 | $41.82 |
| Cost of revenue | ||||
| Gross Profit | $1.58 | $9.69 | $7.57 | $41.82 |
| Operating activities | ||||
| Research & development | $127.8 | $96.94 | $77.55 | $66.19 |
| Selling, general & administrative | $57.93 | $39.95 | $27.56 | $17.27 |
| Total operating expenses | $185.72 | $136.88 | $105.11 | $83.46 |
| Operating income | -$184.15 | -$127.2 | -$97.53 | -$41.65 |
| Income from continuing operations | ||||
| EBIT | -$160.07 | -$122.53 | -$97.26 | -$41.53 |
| Income tax expense | ||||
| Interest expense | $1.27 | $0.79 | ||
| Net income | ||||
| Net income | -$161.34 | -$123.32 | -$97.26 | -$41.53 |
| Income (for common shares) | -$161.34 | -$123.32 | -$97.26 | -$41.53 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$55.85 | -$46.95 | -$41.11 | |
| Operating activities | ||||
| Depreciation | $1.77 | $1.19 | $1.02 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $10.64 | $9.67 | $9.15 | |
| Total cash flows from operations | -$45.3 | -$30.27 | -$25.1 | |
| Investing activities | ||||
| Capital expenditures | -$1.25 | -$1.49 | -$0.06 | |
| Investments | $11.95 | $61.04 | $31.98 | |
| Total cash flows from investing | $101.21 | $10.7 | $59.55 | $31.92 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.68 | $1.88 | $0.23 | |
| Net borrowings | $19.91 | |||
| Total cash flows from financing | $23.02 | $0.68 | $21.79 | $0.22 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $16.38 | -$33.91 | $51.06 | $7.04 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$161.34 | -$123.32 | -$97.26 | -$41.53 |
| Operating activities | ||||
| Depreciation | $4.23 | $3.68 | $3.2 | $1.31 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $44.48 | $22.6 | $10.44 | $3.9 |
| Total cash flows from operations | -$116.36 | -$94.63 | -$75.44 | -$37.27 |
| Investing activities | ||||
| Capital expenditures | -$0.92 | -$1.76 | -$1.95 | -$1.53 |
| Investments | -$126.09 | -$148.44 | $75.65 | -$209.33 |
| Total cash flows from investing | -$127.01 | -$150.2 | $73.7 | -$210.87 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $275.25 | $217.56 | $2.98 | $161.19 |
| Net borrowings | $9.85 | |||
| Total cash flows from financing | $274.4 | $226.85 | $2.53 | $213.21 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $31.03 | -$17.98 | $0.78 | -$34.92 |
News
Fundamentals
| Market cap | $110.14M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 60.85M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$201.68M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.55 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$3.31 |
|---|---|
| ROA | -41.09% |
| ROE | N/A |
| Debt/Equity | 0.08 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 10.26 |
| Quick ratio | N/A |